Investor Presentaiton

Delivering Capex projects to support Future growth 7 CDMO, VTZ^ Animal Health (AH) (LSPL-U2)- Development & Mfg. facility Commercial activities started at 1st block in Oct'23 and further expansion ongoing Agro Chem (LSPL-U4)-mid-scale Intermediates mfg. Small molecules & High Potent (HP) (LSPL-U3) Clinical cGMP mfg capabilities CDMO, HYD^ R&D Center: Small molecules & HP's Clinical Process research development and Drug product development Labs - online from late FY24 BIO, BLR^ Precision Fermentation, AOF r-proteins Expansion at R1 including new R&D block R2: Downstream capability expansion on track for Dec'23 delivery BIO, MYQ^ Synthetic Biology, AOF r-protein (Food) R3: Greenfield/Large scale, commercial fermentation facility (~2Mn liters under Phased manner) New Capacities brought on line in FY23 Expected to come on line in FY24 Future Capex ■ New capacities brought online in FY23 to get Optimally utilized by FY25 ■ US$ 100mn+ CDMO investment on track ■ Commercial activity initiated at AH unit Expect to spend Rs10bn in FY24 Capex ■ H1 Capex reported at ₹ 385 Cr; 16% of Revenues API, VTZ Small molecules (U4/U6)- Expansion of large scale mfg. by 1500KL+ Extended cGMP HPAPIS FDF, VTZ Expansion of small molecules DP capabilities at U2 by 4 billion unit annually Continuous investment in diversified portfolio to support growth momentum A Vizag (VTZ), Hyderabad (HYD), Bangalore (BLR), Mysore (MYQ) Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation